Objective: To investigate the association of CAG repeat numbers in the androgen receptor (AR) gene with female pattern hair loss (FPHL) in a Chinese population. Methods: A total of 200 Han Chinese patients with FPHL (142 Ludwig II and 58 Ludwig III cases) and 200 healthy controls were enrolled in this study. The polymorphism of CAG repeat numbers was analyzed by the fluorescent amplified fragment length polymorphism technique. Results: The CAG biallelic mean length was 23.73 ± 2.04 repeats in Han Chinese FPHL patients and 23.90 ± 2.13 repeats in healthy controls, without any significant difference between the two groups (p = 0.481). In addition, neither the shorter nor the longer CAG repeat numbers were significantly different between FPHL and control subjects (p = 0.726, p = 0.383). Conclusion: The polymorphism of CAG repeat numbers of the AR gene may not be the genetic marker of FPHL in a Chinese population.

1.
Olsen EA: Female pattern hair loss. J Am Acad Dermatol 2001;45(suppl):S70-S80.
2.
Xu F, Sheng YY, Mu ZL, Lou W, Zhou J, Ren YT, Qi SS, Wang XS, Fu ZW, Yang QP: Prevalence and types of androgenetic alopecia in Shanghai, China: a community-based study. Br J Dermatol 2009;160:629-632.
3.
Wang TL, Zhou C, Shen YW, Wang XY, Ding XL, Tian S, Liu Y, Peng GH, Xue SQ, Zhou JE, Wang RL, Meng XM, Pei GD, Bai YH, Liu Q, Li H, Zhang JZ: Prevalence of androgenetic alopecia in China: a community-based study in six cities. Br J Dermatol 2010;162:843-847.
4.
Zhuang XS, Zheng YY, Xu JJ, Fan WX: Quality of life in women with female pattern hair loss and the impact of topical minoxidil treatment on quality of life in these patients. Exp Ther Med 2013;6:542-546.
5.
Messenger AG, Sinclair R: Follicular miniaturization in female pattern hair loss: clinicopathological correlations. Br J Dermatol 2006;155:926-930.
6.
Whiting DA, Waldstreicher J, Sanchez M, Kaufman KD: Measuring reversal of hair miniaturization in androgenetic alopecia by follicular counts in horizontal sections of serial scalp biopsies: results of finasteride 1 mg treatment of men and postmenopausal women. J Investig Dermatol Symp Proc 1999;4:282-284.
7.
Randall VA: Androgens and hair growth. Dermatol Ther 2008;21:314-328.
8.
Yip L, Rufaut N, Sinclair R: Role of genetics and sex steroid hormones in male androgenetic alopecia and female pattern hair loss: an update of what we now know. Australas J Dermatol 2011;52:81-88.
9.
Vujovic A, Del Marmol V: The female pattern hair loss: review of etiopathogenesis and diagnosis. Biomed Res Int 2014;2014:767628.
10.
Chamberlain NL, Driver ED, Miesfeld RL: The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res 1994;22:3181-3186.
11.
Kazemi-Esfarjani P, Trifiro M A, Pinsky L: Evidence for a repressive function of the long polyglutamine tract in the human androgen receptor: possible pathogenetic relevance for the (CAG) n-expanded neuronopathies. Hum Mol Genet 1995;4:523-527.
12.
Ellis JA, Stebbing M, Harrap SB: Polymorphism of the androgen receptor gene is associated with male pattern baldness. J Invest Dermatol 2001;116:452-455.
13.
Pang Y, He CD, Liu Y, Wang KB, Xiao T, WangYK, Zhu H, Wei B, Zhao N, Jiang Y, Wei HC, Chen HD: Combination of short CAG and GGN repeats in the androgen receptor gene is associated with acne risk in North East China. J Eur Acad Dermatol Venereol 2008;22:1445-1451.
14.
Yang Z, Yu H, Cheng B, Tang W, Dong Y, Xiao C, He L: Relationship between the CAG repeat polymorphism in the androgen receptor gene and acne in the Han ethnic group. Dermatology 2009;218:302-306.
15.
Hsing AW, Gao YT, Wu G, Wang X, Deng J, Chen YL, Sesterhenn IA, Mostofi FK, Benichou J, Chang C: Polymorphic CAG and GGN repeat lengths in the androgen receptor gene and prostate cancer risk: a population-based case-control study in China. Cancer Res 2000;60:5111-5116.
16.
Sawaya ME, Shalita AR: Androgen receptor polymorphisms (CAG repeat lengths) in androgenic alopecia, hirsutism, and acne. J Cutan Med Surg 1998;3:1-9.
17.
Suter NM, Malone KE, Daling JR, Doody DR, Ostrander EA: Androgen receptor (CAG)n and (GGC)n polymorphisms and breast cancer risk in a population-based case-control study of young women. Cancer Epidemiol Biomarkers Prev 2003;12:127-135.
18.
Dang J, Peng L, Zhong HJ, Huo ZH: Androgen receptor (CAG)n polymorphisms and breast cancer risk in a Han Chinese population. Genet Mol Res 2015;14:10258-10266.
19.
Platz EA, Rimm EB, Willett WC, Kantoff PW, Giovannucci E: Racial variation in prostate cancer incidence and in hormonal system markers among male health professionals. J Natl Cancer Inst 2000;92:2009-2017.
20.
Zitzmann M, Nieschlag E: The CAG repeat polymorphism within the androgen receptor gene and maleness. Int J Androl 2003;26:76-83.
21.
Wang G1, Chen G, Wang X, Zhong J, Lu J: The polymorphism of (CAG)n repeats within androgen receptor gene among Chinese male population (in Chinese). Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2001;18:456-458.
22.
Yamazaki M, Sato A, Toyoshima KE, Kojima Y, Okada T, Ishii Y, Kurata S, Yoshizato K, Tsuboi R: Polymorphic CAG repeat numbers in the androgen receptor gene of female pattern hair loss patients. J Dermatol 2011;38:680-684.
23.
Keene S, Goren A: Therapeutic hotline. Genetic variations in the androgen receptor gene and finasteride response in women with androgenetic alopecia mediated by epigenetics. Dermatol Ther 2011;24:296-300.
24.
Allen RC, Zoghbi HY, Moseley AB, Rosenblatt HM, Belmont JW: Methylation of HpaII and HhaI sites near the polymorphic CAG repeat in the human androgen-receptor gene correlates with X chromosome inactivation. Am J Hum Genet 1992;51:1229-1239.
25.
Gale RE, Wheadon H, Boulos P, Linch DC: Tissue specificity of X-chromosome inactivation patterns. Blood 1994;83:2899-2905.
26.
Richeti F, Kochi C, Rocha MN, Sant'Anna Corrêa C, Lazzarini R, Guazzelli RM, Mendonça RF, Melo MR, Longui CA: Increased androgen receptor messenger RNA in frontal-parietal hair follicles of women with androgenetic alopecia. Genet Mol Res 2013;12:1834-1840.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.